Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526224 · ClinicalTrials.gov registry record
Teriflunomide Tecfidera LMCE
A clinical trial, sponsored by University at Buffalo.
- Completed
- Registry status
- 120
- Enrollment target
NCT03526224: Completed study, sponsored by University at Buffalo.
NCT03526224 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526224 has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This study will investigate the effect of teriflunomide in reducing cortical gray matter (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl fumarate (Tecfidera®)
Primary Outcome
Percent change in cortical gray matter (CGM) between those on teriflunomide and dimethyl fumarate
Interventions
- DRUG Teriflunomide
- DRUG Dimethyl Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2019-07-10 |
What the finished NCT03526224 record still lists
NCT03526224 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Teriflunomide is the first listed.
NCT03526224 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03526224 about?
NCT03526224 is a clinical study titled "Teriflunomide Tecfidera LMCE". This study will investigate the effect of teriflunomide in reducing cortical gray matter (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl fumarate (Tecfidera®)
What is the current status of trial NCT03526224?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2018-06-14. Estimated completion is 2019-07-10.
What interventions are being tested in trial NCT03526224?
The interventions under investigation include: Teriflunomide (DRUG), Dimethyl Fumarate (DRUG).
Who is sponsoring clinical trial NCT03526224?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI